Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
AssigneeUniversity of Kentucky
InventorJayakrishna Ambati
Life of this patent
Estimating the term…
Abstract
Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and/or prevention of neovascular disease are provided. Also provided are Novel therapeutic targets and diagnostic markers for choroidal neovascularization.
Claims16
A composition for treating and/or preventing choroidal neovascularization (CNV) comprising, a therapeutically effective amount of one or more of, an inactivating agent that binds selectively to activated complement component 3 (C3a), the receptor of C3a (C3aR), activated complement component 5 (C5a), the receptor of C5a (C5aR), or a combination thereof.
A method for inhibiting CNV comprising administering to an eye of a subject a composition comprising one or more of, an inactivating agent to C3a, C3aR, C5a, C5aR, or a combination thereof.
A method for treating and/or preventing age-related macular degeneration (AMD) comprising administering to an eye of a subject a composition comprising:
- a) one or more of, an antagonist to C3a, C3aR, C5a, C5aR or a combination thereof,
- b) one or more of, an antibody to C3a, C3aR, C5a, C5aR, or a combination thereof;
- or
- c) a combination of one or more antagonist of a. and/or one or more antibody of b.
An assay for detecting a predisposition for and/or an early stage of AMD comprising, introducing one or more of, an antibody to C3a, C3aR, C5a, C5aR, or a combination thereof to the eye of a subject, and detecting the presence of C3a, C3aR, C5a C5aR, or a combination thereof in the eye.
Dependencies are inferred from the claim text.